ESCADA: Efficient Safety and Context Aware Dose Allocation for Precision Medicine

• URL: http://arxiv.org/abs/2111.13415v1
• Date: Fri, 26 Nov 2021 10:36:57 GMT
• Title: ESCADA: Efficient Safety and Context Aware Dose Allocation for Precision Medicine
• Authors: Ilker Demirel, Ahmet Alparslan Celik, Cem Tekin
• Abstract summary: Finding an optimal individualized treatment regimen is one of the most challenging precision medicine problems. We propose ESCADA, a generic algorithm for this problem structure. We derive high probability upper bounds on the regret of ESCADA along with safety guarantees.
• Score: 9.023847175654602
• License: http://arxiv.org/licenses/nonexclusive-distrib/1.0/
• Abstract: Finding an optimal individualized treatment regimen is considered one of the most challenging precision medicine problems. Various patient characteristics influence the response to the treatment, and hence, there is no one-size-fits-all regimen. Moreover, the administration of even a single unsafe dose during the treatment can have catastrophic consequences on patients' health. Therefore, an individualized treatment model must ensure patient {\em safety} while {\em efficiently} optimizing the course of therapy. In this work, we study a prevalent and essential medical problem setting where the treatment aims to keep a physiological variable in a range, preferably close to a target level. Such a task is relevant in numerous other domains as well. We propose ESCADA, a generic algorithm for this problem structure, to make individualized and context-aware optimal dose recommendations while assuring patient safety. We derive high probability upper bounds on the regret of ESCADA along with safety guarantees. Finally, we make extensive simulations on the {\em bolus insulin dose} allocation problem in type 1 diabetes mellitus disease and compare ESCADA's performance against Thompson sampling's, rule-based dose allocators', and clinicians'.

Related papers

• Feedback-Based Quantum Control for Safe and Synergistic Drug Combination Design [0.0]
  Drug-drug interactions (DDIs) affect the safety and efficacy of combination therapies.<n>We present a quantum-control-based framework for DDI-aware drug combination optimization.
  arXiv  Detail & Related papers  (2026-01-26T02:30:38Z)
• Constructing optimal treatment length strategies to maximize quality-adjusted lifetimes [5.545853284130158]
  We propose methods for constructing optimal treatment length strategies to maximize quality-adjusted lifetime outcomes. Existing methods for estimating optimal treatment strategies for survival outcomes cannot be applied to a quality-adjusted lifetime due to induced informative censoring. We apply our method to obtain the optimal time for endoscopic gastrostomy insertion in patients with amyotrophic lateral sclerosis.
  arXiv  Detail & Related papers  (2024-12-06T15:09:17Z)
• Quantifying Aleatoric Uncertainty of the Treatment Effect: A Novel Orthogonal Learner [72.20769640318969]
  Estimating causal quantities from observational data is crucial for understanding the safety and effectiveness of medical treatments. Medical practitioners require not only estimating averaged causal quantities, but also understanding the randomness of the treatment effect as a random variable. This randomness is referred to as aleatoric uncertainty and is necessary for understanding the probability of benefit from treatment or quantiles of the treatment effect.
  arXiv  Detail & Related papers  (2024-11-05T18:14:49Z)
• Privacy Preserving Adaptive Experiment Design [13.839525385976303]
  We investigate the tradeoff between loss of social welfare and statistical power in contextual bandit experiment. We propose differentially private algorithms which still matches the lower bound, showing that privacy is "almost free"
  arXiv  Detail & Related papers  (2024-01-16T09:22:12Z)
• Safe and Interpretable Estimation of Optimal Treatment Regimes [54.257304443780434]
  We operationalize a safe and interpretable framework to identify optimal treatment regimes. Our findings support personalized treatment strategies based on a patient's medical history and pharmacological features.
  arXiv  Detail & Related papers  (2023-10-23T19:59:10Z)
• High Dimensional Causal Inference with Variational Backdoor Adjustment [57.31312942774617]
  We take a generative modeling approach to backdoor adjustment for high dimensional treatments and confounders. Our method is able to estimate interventional likelihood in a variety of high dimensional settings, including semi-synthetic X-ray medical data.
  arXiv  Detail & Related papers  (2023-10-09T19:21:41Z)
• Adaptive Semi-Supervised Inference for Optimal Treatment Decisions with Electronic Medical Record Data [18.77246683875067]
  The optimal treatment regime that yields the greatest overall expected clinical outcome of interest has attracted a lot of attention. We consider estimation of the optimal treatment regime with electronic medical record data under a semi-supervised setting.
  arXiv  Detail & Related papers  (2022-03-04T13:54:35Z)
• Policy Learning for Optimal Individualized Dose Intervals [3.9801611649762263]
  We propose a new method to estimate such a policy. We prove that our estimated policy is consistent, and its risk converges to that of the best-in-class policy at a root-nn rate.
  arXiv  Detail & Related papers  (2022-02-24T17:59:20Z)
• Optimal discharge of patients from intensive care via a data-driven policy learning framework [58.720142291102135]
  It is important that the patient discharge task addresses the nuanced trade-off between decreasing a patient's length of stay and the risk of readmission or even death following the discharge decision. This work introduces an end-to-end general framework for capturing this trade-off to recommend optimal discharge timing decisions. A data-driven approach is used to derive a parsimonious, discrete state space representation that captures a patient's physiological condition.
  arXiv  Detail & Related papers  (2021-12-17T04:39:33Z)
• SDF-Bayes: Cautious Optimism in Safe Dose-Finding Clinical Trials with Drug Combinations and Heterogeneous Patient Groups [84.63561578944183]
  This paper proposes a novel Bayesian design, SDF-Bayes, for finding the maximum tolerated dose (MTD) of a drug in a clinical trial. Rather than the conventional principle of escalating or de-escalating the current dose of one drug, SDF-Bayes proceeds by cautious optimism. Extensive experiments based on both synthetic and real-world datasets demonstrate the advantages of SDF-Bayes over state of the art DC trial designs.
  arXiv  Detail & Related papers  (2021-01-26T18:59:26Z)
• Kernel Assisted Learning for Personalized Dose Finding [20.52632915107782]
  An individualized dose rule recommends a dose level within a continuous safe dose range based on patient level information. In this article, we propose a kernel assisted learning method for estimating the optimal individualized dose rule.
  arXiv  Detail & Related papers  (2020-07-19T23:03:26Z)
• DTR Bandit: Learning to Make Response-Adaptive Decisions With Low Regret [59.81290762273153]
  Dynamic treatment regimes (DTRs) are personalized, adaptive, multi-stage treatment plans that adapt treatment decisions to an individual's initial features and to intermediate outcomes and features at each subsequent stage. We propose a novel algorithm that, by carefully balancing exploration and exploitation, is guaranteed to achieve rate-optimal regret when the transition and reward models are linear.
  arXiv  Detail & Related papers  (2020-05-06T13:03:42Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.